english.prescrire.org > Spotlight > 100 most recent > Adverse effects of nirsevimab: limited data after one season of use in infants

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Adverse effects of nirsevimab: limited data after one season of use in infants

 Adverse effects  Nirsevimab is a monoclonal antibody, authorised since 2023 for the prevention of infection with respiratory syncytial virus (RSV) in neonates and infants. Between September 2023 and April 2024, about 2 million children were exposed to nirsevimab worldwide. In September 2024, the French Health Products Agency (ANSM) published the report of a pharmacovigilance survey covering the period from September 2023 to April 2024.
Full article available for download by subscribers

 ©Prescrire 1 January 2026

Source: "Adverse effects of nirsevimab: limited data after one season of use in infants" Prescrire Int 2026; 35 (277): 20-22. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook  
 
 
See also:
 
"Nirsevimab (Beyfortus°)
to prevent RSV infection
in infants. For infants at risk
of developing severe
disease: more convenient
than palivizumab"
Prescrire Int 2023;
32 (254): 285-287.
Subscribers only